Scope: Pilot Project-Sen: COBRE in Pharmaceutical Research and Innovation

Most current therapies in sarcoid, ranging from corticosteroids, Methotrexate to TNF blockers are immunosuppressive agents have significant side effects secondary to systemic immunosuppression. The lack of understanding of the underlying immunopathology of sarcoidosis has hampered the development of novel, targeted therapies. This study will identify specific immune pathway targets in sarcoidosis for development of novel immunomodulatory therapies with lesser side effects. These therapies with lesser side effects will significantly improve quality of life in sarcoid patients by avoiding the need for immunosuppression.